Skip to main
APGE

APGE Stock Forecast & Price Target

APGE Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apogee Therapeutics Inc has seen a notable increase in its stock, rising approximately 19% recently, attributed to optimistic updates regarding the clinical data timeline for its anti-IL-13 therapy, APG777, anticipated to confirm its best-in-class positioning in atopic dermatitis by early 2026. The substantial revenue potential in the market for atopic dermatitis biologics is exemplified by Dupixent’s impressive projected sales growth from $14 billion in 2024 to a minimum of $20 billion, enhancing Apogee's prospects in capturing a share of this expanding market. Additionally, the ongoing growth in new biologic entrants and their efficacy highlights the favorable conditions for Apogee’s innovative therapies, particularly APG777, which are designed to capitalize on existing market demand with optimized therapeutic properties.

Bears say

Apogee Therapeutics faces significant risks that could adversely impact its financial outlook, including the potential for unexpected safety events, suboptimal efficacy, and developmental setbacks from its pipeline programs, which may hinder its ability to successfully prosecute clinical trials. Furthermore, the company's reliance on regulatory approvals for its developmental candidates presents substantial uncertainty, as any failure in this area could severely limit revenue generation and require downward revisions to financial estimates. The overall competitive landscape and potential commercialization challenges further exacerbate the risks, including difficulties in financing ongoing research and development without current revenue streams.

APGE has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apogee Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apogee Therapeutics Inc (APGE) Forecast

Analysts have given APGE a Strong Buy based on their latest research and market trends.

According to 9 analysts, APGE has a Strong Buy consensus rating as of Dec 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apogee Therapeutics Inc (APGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.